TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26328624

Group type: EXPERIMENTAL
Intervention: OM3‐CA 2 g/d
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: OM3‐CA 4 g/d
Number of subjects: 647

Group type: COMPARATOR
Intervention: Control (olive oil, OO) 4 g/d
Number of subjects: 647
Study: 23113989

Group type: EXPERIMENTAL
Intervention: Group balance training three times per week during 12 weeks
Number of subjects: 59
Study: 21734600

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (200 mg, twice per day for 5 days)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 18815571

Group type: EXPERIMENTAL
Intervention: Ballistic resistance training (8 weeks, 3 days per week, loading between 26 and 48% of 1RM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 14
Study: 16180383

Group type: EXPERIMENTAL
Intervention: CAD/CAM method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual method
Number of subjects: 40
Study: 15074449

Group type: EXPERIMENTAL
Intervention: Cessation services received by smokers with COPD (advised to quit, prescribed nicotine patches, referred to a smoking cessation program)
Number of subjects: 1941

Group type: COMPARATOR
Intervention: Cessation services received by smokers without COPD
Number of subjects: 1941

Group type: EXPERIMENTAL
Intervention: Cessation services received by smokers with COPD not interested in quitting
Number of subjects: 1941
Study: 10380968

Group type: EXPERIMENTAL
Intervention: Examination of fresh blood samples from patients with Alzheimer's disease
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Examination of fresh necropsy brain cortical specimens from AD patients
Number of subjects: 22
Study: 8874076

Group type: EXPERIMENTAL
Intervention: polyI:polyC12U (400 or 700 mg) with zidovudine
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo with zidovudine
Number of subjects: 36
Study: 1502478

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for 6 months
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298

Group type: COMPARATOR
Intervention: Prior omeprazole therapy
Number of subjects: 298

Group type: COMPARATOR
Intervention: Duration of pre‐trial symptomatic period
Number of subjects: 298

Group type: COMPARATOR
Intervention: Initial endoscopic severity grade
Number of subjects: 298
Study: 6711668

Group type: EXPERIMENTAL
Intervention: Jumping rope (purposeful activity)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Jumping in place without a rope (nonpurposeful activity)
Number of subjects: 26
Study: 30962264

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.4 μg/(kg · min) for 10 min before surgery
Number of subjects: 134

Group type: COMPARATOR
Intervention: Equivalent saline
Number of subjects: 134
Study: 29437119

Group type: EXPERIMENTAL
Intervention: RVPAS
Number of subjects: 549

Group type: COMPARATOR
Intervention: Modified Blalock-Tausig shunt
Number of subjects: 549
Study: 27312678

Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC) once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 200 mm Hg, followed by 5 min of reperfusion.
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Sham treatment once daily for 12 months, consisting of five cycles of 5 min of pressure treatment at 60 mm Hg, followed by 5 min of reperfusion.
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC)
Number of subjects: 1500
Study: 25326750

Group type: EXPERIMENTAL
Intervention: 2013 GOLD classification stages A-D
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 2013 GOLD classification stages 2-4
Number of subjects: 1000
Study: 22499291

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: β-blocker
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24-h BP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic BP
Number of subjects: 0
Study: 20364590

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (120 mg/d for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 19091199

Group type: EXPERIMENTAL
Intervention: Pio+SU (pioglitazone plus sulfonylurea)
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Pio+Met (pioglitazone plus metformin)
Number of subjects: 2294

Group type: COMPARATOR
Intervention: SU+Met (sulfonylurea plus metformin)
Number of subjects: 2294
Study: 17325222

Group type: EXPERIMENTAL
Intervention: artesunate
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Number of subjects: 360

Group type: COMPARATOR
Intervention: amodiaquine
Number of subjects: 360
Study: 12946882

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10831027

Group type: EXPERIMENTAL
Intervention: pindolol 2.5 mg three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo three times daily
Number of subjects: 20
Study: 9091392

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) 5.9 g/d
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (stools collected at least 24 h after the last fecal excretion of PEG)
Number of subjects: 16
Study: 8469466

Group type: COMPARATOR
Intervention: Erythromycin 500 mg four times daily for 7 days
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg three times daily for 7 days
Number of subjects: 143
Study: 3921142

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study: 30849305

Group type: EXPERIMENTAL
Intervention: Woman's Condom (WC)
Number of subjects: 405
Study: 29990228

Group type: EXPERIMENTAL
Intervention: Smartphone-based adjunct to standard care (three devices: smartphone with app, portable blood pressure monitor, weight scale)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Smartphone-based adjunct to standard care
Number of subjects: 66
Study: 26636422

Group type: EXPERIMENTAL
Intervention: Single dose of febuxostat 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of febuxostat 80 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of febuxostat 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple dose of febuxostat 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple dose of febuxostat 80 mg
Number of subjects: 12
Study: 23979914

Group type: COMPARATOR
Intervention: Etanercept (ETN) monotherapy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) + Methotrexate (MTX) combination therapy
Number of subjects: 205
Study: 21997881

Group type: EXPERIMENTAL
Intervention: Flaxseed pillow treatment (two 15-minute treatments per day for the first 5 days of life)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flaxseed pillow treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 20088009

Group type: EXPERIMENTAL
Intervention: Percutaneous transcatheter delivery of dedicated LAA exclusion devices (PLAATO device, Watchman device, Amplatzer cardiac plug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 0
Study: 18397921

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 142

Group type: COMPARATOR
Intervention: Propofol-based TIVA
Number of subjects: 142
Study: 16362849

Group type: EXPERIMENTAL
Intervention: GSPECT-QGS
Number of subjects: 200
Study: 14614003

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (i.p.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to subcutaneous (s.c.) at 4 weeks.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of Flt3-L (25 micro g/kg, maximum 1500 micro g), days 1-5 and 8-12, then changed to intraperitoneal (i.p.) at 4 weeks.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both i.p. and s.c. administration of Flt3-L.
Number of subjects: 15
Study: 10585173

Group type: EXPERIMENTAL
Intervention: Menorest
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tradelia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Estraderm MX
Number of subjects: 21
Study: 9114872

Group type: EXPERIMENTAL
Intervention: CBE training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 1754109

Group type: EXPERIMENTAL
Intervention: Internal jugular catheter
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subclavian catheter
Number of subjects: 100
Study: 6827423

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (albuterol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcutaneous epinephrine
Number of subjects: 40
Study: 31908395

Group type: EXPERIMENTAL
Intervention: Same admission (SA) cholecystectomy
Number of subjects: 554

Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Same admission (SA) cholecystectomy (Tokyo Grade 2)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Delayed cholecystectomy (Tokyo Grade 2)
Number of subjects: 554
Study: 30054629

Group type: EXPERIMENTAL
Intervention: Peer-mediated approach with speech-generating device (SGD) intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Business-as-usual comparison condition with untrained peers
Number of subjects: 140
Study: 27276999

Group type: EXPERIMENTAL
Intervention: Dextromethorphan/quinidine (DM/Q) 20/10 mg twice daily
Number of subjects: 367
Study: 24566440

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (MC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 22192488

Group type: EXPERIMENTAL
Intervention: Annual azithromycin treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Twice-yearly azithromycin treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of annual vs twice-yearly treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Twice-yearly treatment
Number of subjects: 24
Study: 21067381

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 234
Study: 17928466

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Conversion to mycophenolate mofetil
Number of subjects: 32
Study: 16551480

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Bipolar diathermy tonsillectomy
Number of subjects: 204
Study: 11881868

Group type: COMPARATOR
Intervention: Peribulbar block with 5 ml of 1:1 mixture of 0.5% plain bupivacaine and 2% lignocaine supplemented with hyaluronidase 300 i.u. ml(‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Deep topical fornix nerve block anaesthesia (DTFNBA) with placement of a sponge soaked in 0.5% bupivacaine deep into the conjunctival fornices for 15 min
Number of subjects: 100
Study: 10211536

Group type: EXPERIMENTAL
Intervention: Lovastatin 10 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Lovastatin 20 mg (Control)
Number of subjects: 93
Study: 7638815

Group type: EXPERIMENTAL
Intervention: Salmeterol/HFA134a inhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Current salmeterol inhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (HFA134a)
Number of subjects: 12
Study: 2611069

Group type: EXPERIMENTAL
Intervention: Fluid preloading with 1 litre of crystalloid fluid given at a rate of 1000 ml in 15 min before spinal anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: No preload group (1 ml min‐1 fluid rate)
Number of subjects: 40
Study: 328335

Group type: EXPERIMENTAL
Intervention: 2 Brom‐alpha‐ergokryptin (Cb 154)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sexual steroids (Estrovis 4000)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lisurid‐hydrogenmaleate (LHM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30977980

Group type: EXPERIMENTAL
Intervention: Single oral dose of glasdegib 100 mg (tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single intravenous (IV) dose of glasdegib 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glasdegib oral administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral tablet administration
Number of subjects: 12
Study: 28547942

Group type: EXPERIMENTAL
Intervention: Watching a DVD
Number of subjects: 984

Group type: COMPARATOR
Intervention: Reading printed materials
Number of subjects: 984
Study: 26610558

Group type: EXPERIMENTAL
Intervention: TheaTrim (Purus Labs; containing a branded form of theacrine (Teacrine™) and caffeine (150 mg))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Caffeine only (150 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23628190

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21940220

Group type: EXPERIMENTAL
Intervention: 12 mm Hg intraabdominal pressure (n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 10 mm Hg intraabdominal pressure (n = 100)
Number of subjects: 200
Study: 19673326

Group type: EXPERIMENTAL
Intervention: Aidi Injection combined with radiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 60
Study: 16703653

Group type: EXPERIMENTAL
Intervention: Liver resection with hepatic pedicle clamping
Number of subjects: 126

Group type: COMPARATOR
Intervention: Liver resection without hepatic pedicle clamping
Number of subjects: 126
Study: 15094532

Group type: EXPERIMENTAL
Intervention: Multiaxial pedicle screws
Number of subjects: 30
Study: 16883915

Group type: EXPERIMENTAL
Intervention: Wenxin Granule (WXG) and amiodarone
Number of subjects: 224

Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 224
Study: 10586394

Group type: EXPERIMENTAL
Intervention: Linezolid 375 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aztreonam 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linezolid 375 mg plus Aztreonam 1000 mg
Number of subjects: 0
Study: 7537913

Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard combination regimens: CMF or CAF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAF (Cyclophosphamide/Doxorubicin/5-Fluorouracil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide/Methotrexate/5-Fluorouracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer agents (Paclitaxel, Docetaxel, Vinorelbine, Amonafide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leucovorin/5-Fluorouracil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel approaches (differentiating agents, anti-angiogenesis factors, antitumor antigen-based therapy, growth factor receptor/ligand therapy, gene therapy)
Number of subjects: 0
Study: 2030804

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg o.d. (n = 62)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d. (n = 63)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Atenolol/nifedipine combination
Number of subjects: 125

Group type: COMPARATOR
Intervention: Captopril/nifedipine combination
Number of subjects: 125
Study: 6786635

Group type: EXPERIMENTAL
Intervention: Water-soluble extract of karela (Momordica charantia)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fried karela fruits consumed as a daily supplement
Number of subjects: 15
Study: 30076692

Group type: EXPERIMENTAL
Intervention: 250 µs; 50 Hz TENS program
Number of subjects: 80

Group type: COMPARATOR
Intervention: 50 µs; 2 Hz TENS program (Control)
Number of subjects: 80
Study: 28119114

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel
Number of subjects: 110

Group type: COMPARATOR
Intervention: Classic wound dressing (control)
Number of subjects: 110
Study: 26842665

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 24 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Maltodextrin (MD) 24 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 14
Study: 24476806

Group type: EXPERIMENTAL
Intervention: Unrestricted group (less restricted hip movement and assistive devices according to individual needs)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Restricted group (rehabilitation with restrictions in hip movement and a standard package of assistive devices)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 365
Study: 23155025

Group type: COMPARATOR
Intervention: Control diet based on corn and soybean meal formulated with 22% CP (dig Gly+Ser:Lys ratio of 147)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Diet with a 3% CP reduction (19% CP) and a Gly+Ser:Lys ratio of 127
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Diets with a 3% CP reduction (19% CP)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Diets with increased dig Gly+Ser:Lys ratios from 127 to 137 and 147
Number of subjects: 1050
Study: 19863455

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 652

Group type: COMPARATOR
Intervention: BZA 20 mg
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 17435957

Group type: EXPERIMENTAL
Intervention: Soy milk (72 mg isoflavones/day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cow's milk and isoflavone supplement (70 mg isoflavones/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cow's milk and placebo supplement (control)
Number of subjects: 79
Study: 15788292

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg once daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 44
Study: 11896339

Group type: EXPERIMENTAL
Intervention: IV fluid replacement (500 mL of HES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No fluid replacement
Number of subjects: 60
Study: 9442159

Group type: EXPERIMENTAL
Intervention: Sweeping of membranes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (vaginal examination for Bishop scoring only)
Number of subjects: 200
Study: 8576296

Group type: EXPERIMENTAL
Intervention: 3.5 mg intravenous glyburide (Gb)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3.5 mg intravenous 4‐trans‐hydroxyglibenclamide (M1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3.5 mg intravenous 3‐cis‐hydroxyglibenclamide (M2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 3.5 mg oral micronized glyburide (Gb)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of intravenous and oral administration of glyburide
Number of subjects: 8
Study: 2198414

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg daily, non-supervised for 3 years
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: RMP 900 mg supervised, once weekly, 8 doses
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: RMP 600 mg, once monthly, supervised, 6 doses with dapsone 100 mg daily unsupervised
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: RMP 600 mg together with dapsone 100 mg daily, supervised for 6 days
Number of subjects: 195

Group type: COMPARATOR
Intervention: Classical dapsone treatment
Number of subjects: 195
Study: 30289444

Group type: EXPERIMENTAL
Intervention: Low-dose ring (VCV, 91 mg; MK-2048, 10 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Original-dose ring (VCV, 182 mg; MK-2048, 30 mg)
Number of subjects: 19
Study: 30208766

Group type: EXPERIMENTAL
Intervention: Pentaclethra macrophylla (akpaka) sauce
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Steamed bambara groundnut pudding (okpa)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Maize + pigeon pea (ayaraya oka)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tomato stew
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pterocarpus soyauxii (oha) soup
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Yam + pigeon pea (ayaraya ji)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Various foods
Number of subjects: 90
Study: 28275807

Group type: EXPERIMENTAL
Intervention: Semiconductor laser therapy combined with botulinum toxin A type injection (50 U injected into masseteric and temporal muscles, 5 injections at different sites on each side, treatment course of 2 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Semiconductor laser therapy (once per day for 1 week)
Number of subjects: 90
Study: 24673738

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei 01 supplementation (10^8 CFU, one capsule daily for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei 01 supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22301766

Group type: EXPERIMENTAL
Intervention: 400 mg eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) and 2 g α-linolenic acid (ALA)
Number of subjects: 4153

Group type: EXPERIMENTAL
Intervention: EPA-DHA plus ALA
Number of subjects: 4153
Study: 19159691

Group type: EXPERIMENTAL
Intervention: Verum acupuncture with high expectation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture with high expectation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 17109475

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 12

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 12

Group type: COMPARATOR
Intervention: FREE AA
Number of subjects: 12
Study: 15185464

Group type: EXPERIMENTAL
Intervention: Equivalence trials in cardiovascular medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-inferiority trials in cardiovascular medicine
Number of subjects: 0